Under Strict Embargo until 00.01 (BST) 8th October 2009
+44(0) 1243 770 375
Stem Cells Which “Fool Immune System” May Provide Vaccination for Cancer
North Carolina, October, 2009 – Scientists from the United States and China have revealed the potential for human stem cells to provide a vaccination against colon cancer, reports a study published in STEM CELLS.
This discovery, led by experts in immunology, Dr. Bei Liu and Dr. Zihai Li, builds upon a century old theory that immunizing with embryonic materials may generate an anti-tumour response. However, this theory has never before been advanced beyond animal research so the discovery that human stem cells are able to immunize against colon cancer is both new and unexpected.
"This finding potentially opens up a new paradigm for cancer vaccine research,” said Dr. Zihai Li. “Cancer and stem cells share many molecular and biological features. By immunizing the host with stem cells, we are able to ‘fool’ the immune system to believe that cancer cells are present and thus to initiate a tumor-combating immune program."
The research is the first of its kind to implicate the role of human stem cells in vaccinating against colon cancer, and represents collaboration between the prestigious laboratories of Dr. Zihai Li and stem cell expert Dr. Renhe Xu at the University of Connecticut Stem Cell Institute.
The team vaccinated laboratory mice with human embryonic stem (hES) cells and discovered a consistent immune response against colon cancer cells. The team witnessed dramatic decline in tumor growth within the immunized mice. This revealed that immunized mice could generate a strong anti-tumour response through the application of hES cells.
The team also discovered that while natural embryonic stem cells are able to provide a response, artificially induced pluripotent stem cells (iPSC) are not. This is significant as it challenges the theory that iPSC are the same as hES cells and may replace them at the forefront of stem cell research.
"Although we have only tested the protection against colon cancer, we believe that stem cells might be useful for generating an immune response against a broad-spectrum of cancers, thus serving as a universal cancer vaccine," concluded Dr. Bei Liu.
This paper is published in STEM CELLS.
Media wishing to request a copy should contact Ben Norman on Lifesciencenews@wiley.com
or +44 (0) 1243 770 375
Full Citation: Li.Y, Hui.Z, Ren-He.X, Bei.L, Z.Li “Vaccination with Human Pluripotent Stem Cells Generates A Broad Spectrum of Immunological And Clinical Response Against Colon Cancer”, STEM CELLS, 2009, DOI: 10.1002/stem.234
About the Author: The first author of this paper is Dr. Yi Li, M.D., who performed this work in the laboratory of Dr. Zihai Li, MD, PhD. The two corresponding authors are Dr. Bei Liu, M.D., M.P.H. and Dr. Zihai Li. Dr Zihai Li is based at the Department of Immunology at the University of Connecticut Health Centre. His research focuses on the mechanism of immune regulation by the innate immunity in the context of tumors, infections and autoimmune diseases.
Media wishing to contact Dr Li should do so via the Communications Officer Carolyn Pennington,
860-679-4864 or firstname.lastname@example.org
About STEM CELLS: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. For more information, please visit:
STEM CELLS is co-published by AlphaMed Press and Wiley-Blackwell.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC and Craigavon, United Kingdom publishes two internationally renowned peer-reviewed journals: STEM CELLS®, now in its 27th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, is in its 14th year and is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. Both journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. AlphaMed Press publishes the Stem Cells Portal online (www.StemCellsPortal.com), as well as freestanding monographs and books, and is renowned for its excellence and speed in the publication of the peer-reviewed proceedings of major international symposia. For more information on AlphaMed Press, please visit www.alphamedpress.org.
About Wiley-Blackwell: Wiley-Blackwell is the international scientific, technical, medical and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley-Blackwell publishes over 1,500 peer-reviewed journals as well as 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or www.interscience.wiley.com.
Unsubscribe: We received your name from a reputable media service. If you would rather not receive messages from Journal News about publicity in this subject area, please click here. If you would like to be removed from the media service, please contact Cision at email@example.com.